Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals by Sharma, Monika et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2009, p. 3256–3265 Vol. 53, No. 8
0066-4804/09/$08.000 doi:10.1128/AAC.01497-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Curcumin Modulates Efflux Mediated by Yeast ABC Multidrug
Transporters and Is Synergistic with Antifungals
Monika Sharma,1 Raman Manoharlal,1 Suneet Shukla,2 Nidhi Puri,1 Tulika Prasad,1,3
Suresh V. Ambudkar,2 and Rajendra Prasad1*
Membrane Biology Laboratory, School of Life Sciences,1 and Advanced Instrumentation Facility,
University Science Instrumentation Centre,3 Jawaharlal Nehru University, New Delhi 110 067,
India, and Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland 208922
Received 9 November 2008/Returned for modification 12 February 2009/Accepted 11 May 2009
Curcumin (CUR), a natural product of turmeric, from rhizomes of Curcuma longa, is a known agent of
reversal of drug resistance phenotypes in cancer cells overexpressing ATP-binding cassette (ABC) transport-
ers, viz., ABCB1, ABCG2, and ABCC1. In the present study, we evaluated whether CUR could also modulate
multidrug transporters of yeasts that belong either to the ABC family or to the major facilitator superfamily
(MFS). The effect of CUR on multidrug transporter proteins was demonstrated by examining rhodamine 6G
(R6G) efflux in Saccharomyces cerevisiae cells overexpressing the Candida albicans ABC transporters Cdr1p and
Cdr2p (CaCdr1p and CaCdr2p, respectively) and the MFS transporters CaMdr1p and S. cerevisiae Pdr5p.
CUR decreased the extracellular concentration of R6G in ABC transporter-expressing cells but had no effect
on methotrexate efflux mediated through the MFS transporter CaMdr1p. CUR competitively inhibited R6G
efflux and the photolabeling of CaCdr1p by [125I]iodoarylazidoprazosin, a drug analogue of the substrate
prazosin (50% inhibitory concentration, 14.2 M). Notably, the mutant variants of CaCdr1p that displayed
abrogated efflux of R6G also showed reduced modulation by CUR. Drug susceptibility testing of ABC protein-
expressing cells by spot assays and checkerboard tests revealed that CUR was selectively synergistic with drug
substrates such as R6G, ketoconazole, itraconazole, and miconazole but not with fluconazole, voriconazole,
anisomycin, cycloheximide, or FK520. Taken together, our results provide the first evidence that CUR mod-
ulates only ABC multidrug transporters and could be exploited in combination with certain conventional
antifungal drugs to reverse multidrug resistance in Candida cells.
Overexpression of ATP-binding cassette (ABC) multidrug
transporters, including P-glycoprotein (ABCB1), multidrug re-
sistance protein (ABCC1), and mitoxantrone resistance pro-
tein (ABCG2), plays a major role in the development of mul-
tidrug resistance (MDR) in cancer cells (19). Among the
various strategies to combat MDR, blocking the functioning of
MDR transporters represents an attractive approach (11). No-
tably, several functional inhibitors of MDR proteins have been
tested, but thus far none are clinically successful, due to the
dose-limiting toxic effect of the modulators.
To circumvent this problem, extensive efforts have been
under way in recent years to identify natural inhibitors of
MDR exporters, since natural products have the potential to
yield a large number of new drugs. Curcuminoids, from the
rhizomes of Curcuma longa, have been reported to reverse the
drug resistance phenotype in cancer cells overexpressing ABC
transporters, viz., ABCB1, ABCG2, and ABCC1 (2, 4, 5). Cur-
cuminoids blocked the efflux of fluorescent substrates calcein
AM, rhodamine 123, and bodipy-FL-vinblastine in MDR cer-
vical carcinoma cell lines overexpressing ABCB1 and the efflux
of mitoxantrone and pheophorbide A, mediated by ABCG2, in
HEK293 cells (3, 4).
In yeasts, including species of the pathogenic genus Candida,
upregulation of multidrug transporter genes belonging either
to the ABC family or to the major facilitator superfamily
(MFS) is frequently observed in cells exposed to drugs and
leads to the phenomenon of MDR (29, 31, 32). For clinical
isolates of Candida albicans, it has been established that the
ABC transporters C. albicans Cdr1p (CaCdr1p) and CaCdr2p
and the MFS transporter CaMdr1p are major MDR transport-
ers that contribute to azole resistance. There are compounds,
such as FK506, enniatins, milbemycins, synthetic D-octapep-
tides, cyclosporine, isonitrile, disulfiram, ibuprofen, and unnar-
micins (12, 30), that inhibit fungal ABC transporters. Such
inhibitors or chemosensitizers probably act directly by affecting
substrate binding and transport mediated by MDR efflux pro-
teins.
Notably, the effect of curcuminoids on fungal ABC trans-
porters is not known. However, due to functional and struc-
tural similarities between ABCB1 and ABC transporters in
yeasts, it is very likely that the curcuminoids could act as
“reversal agents” of drug resistance in yeasts as well. In this
study, we have examined the potency of curcumin (CUR) in
modulating the efflux activity of CaCdr1p and have compared
it with those of CaCdr2p and Saccharomyces cerevisiae Pdr5p
(ScPdr5p). Our results demonstrate that CUR behaves as a
specific modulator of rhodamine 6G (R6G) efflux mediated by
CaCdr1p, CaCdr2p, and ScPdr5p in S. cerevisiae cells overex-
pressing these transporters. Notably, CUR had no impact on
efflux activity mediated by the MFS transporter CaMdr1p.
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Furthermore, CUR reversed drug resistance by displaying syn-
ergism with selected drugs.
MATERIALS AND METHODS
Materials. R6G, a commercial-grade mixture of curcuminoids (commonly
known as CUR), protease inhibitors (phenylmethylsulfonyl fluoride, leupeptin,
aprotinin, pepstatin A, N-p-tosyl-L-lysine chloromethyl ketone [TLCK], and
N-tosyl-L-phenylalanine chloromethyl ketone [TPCK]), a bicinchoninic acid pro-
tein determination kit, miconazole (MCZ), ketoconazole (KTC), itraconazole
(ITC), anisomycin (ANISO), cycloheximide (CYH), FK520, oligomycin, dinitro-
phenol, deoxyglucose, 3-(4,5-dimethyl thiazol-2-yl)-2,5 diphenyl tetrazolium bro-
mide (MTT), and other molecular-grade chemicals were obtained from Sigma
Chemical Co. (St. Louis, MO). [3H]-labeled fluconazole (FLC; specific activity,
19 Ci/mmol) was custom synthesized by Amersham Biosciences, United King-
dom, and [3H]methotrexate (MTX; specific activity, 8.60 Ci/mmol) was procured
from Amersham Biosciences, United Kingdom. Radiolabeled [125I]iodoarylazi-
doprazosin (IAAP) (2,200 Ci/mmol) was purchased from Perkin-Elmer Life
Sciences (Boston, MA).
Yeast strains and growth media. The strains used in this study are listed in
Table 1. The yeast strains were cultured in yeast extract-peptone-dextrose
(YEPD) broth (Bio 101, Vista, CA). For agar plates, 2.5% (wt/vol) Bacto agar
(Difco, BD Biosciences, NJ) was added to the medium. All strains were stored
as frozen stocks with 15% glycerol at 80°C. Before each experiment, cells were
freshly revived on YEPD plates from the stock.
Efflux of R6G. The efflux of R6G was determined essentially using a previously
described protocol (27). Briefly, approximately 1  106 yeast cells from an
overnight-grown culture were transferred to YEPD medium and allowed to grow
for 5 h. Cells were pelleted, washed twice with phosphate-buffered saline (PBS)
(without glucose), and resuspended as a 2% cell suspension, which corresponds
to 108 cells (wt/vol) in PBS without glucose. The cells were then de-energized for
45 min in deoxyglucose (5 mM) and dinitrophenol (5 mM) in PBS (without
glucose). The de-energized cells were pelleted, washed, and then resuspended as
a 2% cell suspension (wt/vol) in PBS without glucose, to which R6G was added
at a final concentration of 10 M and incubated for 40 min at 30°C. The
equilibrated cells with R6G were then washed and resuspended as a 2% cell
suspension (wt/vol) in PBS without glucose. Samples with a volume of 1 ml were
withdrawn at the indicated time and centrifuged at 9,000  g for 2 min. The
supernatant was collected, and absorption was measured at 527 nm. Energy-
dependent efflux (at the indicated time) was measured after the addition of
glucose (2%) to the cells resuspended in PBS (without glucose). Glucose-free
controls were included in all the experiments. For competition assays, CUR (100
M) was added to the de-energized cells 5 min before the addition of R6G and
allowed to equilibrate.
Measurement of drug accumulation. The accumulation of [3H]FLC (specific
activity, 19 Ci/mmol) and [3H]MTX (specific activity, 8.60 Ci/mmol) was deter-
mined essentially by the methods described previously (22). Briefly, cells from
mid-log phase (5 106) were centrifuged at 3,000 g for 3 min and resuspended
in PBS as a 2% cell suspension. For accumulation studies, 100 nM FLC and 25
M MTX were routinely used (22). CUR at 100 M was added 5 min before the
addition of drugs and was allowed to equilibrate. A 100-l volume of the cell
suspension containing drugs alone or drugs plus CUR was incubated at 30°C for
40 min, filtered rapidly, and washed twice with PBS (pH 7.4) on a Millipore
manifold filter assembly using a 0.45-m-pore size cellulose nitrate filter (Milli-
pore). The filter discs were dried and put in cocktail “O,” and the radioactivity
was measured in a liquid scintillation counter (Beckman). Accumulation was
expressed as picomoles per milligram (dry weight).
Photoaffinity labeling with IAAP. The crude membrane proteins (50 g) pre-
pared from AD-CDR1 cells (27) were incubated with CUR or with R6G for 10
min at 37°C in 0.1 ml of 50 mM Tris-HCl (pH 7.5). The samples were brought to
room temperature, and 3 to 6 nM [125I]IAAP (2,200 Ci/mmol) was added and
incubated for an additional 5 min under subdued light. The samples were then
illuminated with a UV lamp assembly (PGC Scientifics, Gaithersburg, MD) fitted
with two black-light (self-filtering) UVA long-wavelength F15T8BLB tubes (365
nm) for 10 min at room temperature (21 to 23°C). One milliliter of radioimmu-
noprecipitation assay buffer was added to the samples, and CaCdr1p cross-linked
with [125I]IAAP was immunoprecipitated with 10 g of a monoclonal antibody
(BD Biosciences, Palo Alto, CA) against green fluorescent protein (GFP) (27).
The samples were then separated on a 7% Tris-acetate gel at a constant voltage,
and the gels were dried and exposed to Bio-Max MR film (Eastman Kodak,
Rochester, NY) at 80°C for 12 to 24 h. The radioactivity incorporated into the
CaCdr1p band was quantified using a Storm 860 PhosphorImager system (Mo-
lecular Dynamics, Sunnyvale, CA) and ImageQuant software as described pre-
viously (27).
ATPase assay. The ATPase activity of the plasma membrane (PM) fractions
was measured as oligomycin-sensitive release of inorganic phosphate either
alone, as described previously (27), or in the presence of CUR (100 M) and
varying concentrations of ATP (0.5 mM to 7 mM).
Immunodetection of ABC proteins. PMs were prepared from S. cerevisiae cells
overexpressing ABC transporters as described previously (27) or in the presence
of CUR (100 M). The PM protein concentration was determined by a bicin-
choninic acid assay using bovine serum albumin as the standard. Western blot
TABLE 1. Strains used in this study
Strain
no.
Strain name
or mutation Genotype or description
a Source
1 AD1-8u MAT pdr1-3 his1 ura yor1::hisG snq2::hisG pdr5::hisG pdr10::hisG
pdr11::hisG ycf1::hisG pdr3::hisG pdr15::hisG
7
2 AD-CDR1 AD1-8u cells harboring the CaCDR1-GFP ORF integrated at the PDR5 locus 27
3 A1346G CDR1-GFP cells carrying an A1346G mutation in the CDR1 ORF and integrated at
the PDR5 locus
24
4 A1347G CDR1-GFP cells carrying an A1347G mutation in the CDR1 ORF and integrated at
the PDR5 locus
24
5 T1351A CDR1-GFP cells carrying a T1351A mutation in the CDR1 ORF and integrated at
the PDR5 locus
24
6 F1360A CDR1-GFP cells carrying an F1360A mutation in the CDR1 ORF and integrated at
the PDR5 locus
24
7 G1362A CDR1-GFP cells carrying a G1362A mutation in the CDR1 ORF and integrated at
the PDR5 locus
24
8 L1358A CDR1-GFP cells carrying an L1358A mutation in the CDR1 ORF and integrated at
the PDR5 locus
24
9 T1355A CDR1-GFP cells carrying a T1355A mutation in the CDR1 ORF and integrated at
the PDR5 locus
24
10 G682A CDR1-GFP cells carrying a G682A mutation in the CDR1 ORF and integrated at
the PDR5 locus
Puri et al.,
unpublished data
11 AD-CaMDR1 AD1-8u cells harboring the CaMDR1-GFP ORF integrated at the PDR5 locus 22
12 AD-CDR2 AD1-8u cells harboring the CaCDR2-GFP ORF integrated at the PDR5 locus 17
13 AD-PDR5 AD1-8u cells harboring the ScPDR5-GFP ORF integrated at the PDR5 locus 17
14 CAI4 ura3::imm434/ura3::imm434 8
a ORF, open reading frame.
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FIG. 1. Effects of CUR on efflux of substrates in yeast cells. (A) Extracellular R6G concentrations in S. cerevisiae control cells (AD1-8u) (diamonds)
and in cells overexpressing CaCdr1p (AD-CDR1) (squares), incubated either with R6G (10 M) alone (filled symbols) or with R6G plus CUR (100 M)
(open symbols). Filled triangles represent AD-CaMDR1 cells. Energy-dependent R6G efflux was initiated by adding 2% glucose (arrow) and was
quantified by measuring the absorbance of the supernatant at 527 nm. Values are means and standard deviations (error bars) for three independent
experiments. (B) [3H]MTX accumulation in S. cerevisiae control cells (AD1-8u) and in cells overexpressing CaMdr1p (AD-CaMDR1). Cells were
incubated either with [3H]MTX (25 M; specific activity, 8.60 Ci/mmol) alone (shaded bars) or with [3H]MTX plus CUR (100 M) (open bars). The
solid black bar represents AD-CDR1 cells. The accumulated [3H]MTX was measured, 40 min after the initiation of efflux, using a liquid scintillation
counter (Beckman). Values are means standard deviations (error bars) for three independent experiments. (C) [3H]FLC accumulation in S. cerevisiae
control cells and in cells overexpressing CaCdr1p. Cells were incubated with either [3H]FLC (100 nM; specific activity, 19 Ci/mmol) alone (filled bars)
or [3H]FLC plus CUR (100 M) (open bars). The accumulated [3H]FLC was measured 40 min after the addition of glucose (2%). Values are means
standard deviations (error bars) for three independent experiments. (D) Extracellular R6G concentrations in C. albicans strain CAI4. Cells were
incubated either with R6G (10M) alone (filled triangles) or with R6G plus CUR (100M) (open triangles). Energy-dependent R6G efflux was initiated
by adding 2% glucose (arrow) and was quantified by measuring the absorbance of the supernatant at 527 nm. Values are means and standard deviations
(error bars) for three independent experiments. (E) Extracellular R6G concentrations in S. cerevisiae control cells (AD1-8u) (diamonds) and in cells
overexpressing CaCdr2p (AD-CDR2) (squares) incubated either with R6G (10 M) alone (filled symbols) or with R6G plus CUR (100 M) (open
symbols). (F) Extracellular R6G concentrations in S. cerevisiae control cells (AD1-8u) (diamonds) and in cells overexpressing ScPdr5p (AD-PDR5)
(squares), incubated either with R6G (10 M) alone (filled symbols) or with R6G plus CUR (100 M) (open symbols). Energy-dependent R6G efflux
was initiated by the addition of 2% glucose (arrows) and was quantified by measuring the absorbance of the supernatant at 527 nm. Values are means
and standard deviations (error bars) for three independent experiments.
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analysis was conducted using an anti-GFP monoclonal antibody (1:5,000) as
described previously (27). Proteins on immunoblots were visualized using the
enhanced chemiluminescence assay system (ECL kit; Amersham Biosciences,
Arlington Heights, IL).
Drug susceptibility assay. The sensitivities of yeast cells to different drugs in
the presence of CUR were determined by spot assays as described previously
(22). The interaction of CUR with KTC, MCZ, ITC, R6G, FLC, ANISO, CYH,
FK520, or MTX was evaluated by the checkerboard method recommended by
the CLSI (formerly NCCLS) and was expressed as the fractional inhibitory
concentration (FIC) index, the sum of the FICs for each agent. The FIC of each
agent is calculated as the MIC of the agent in combination divided by the MIC
of the agent alone (21). A range of concentrations were tried: 0.202 to 208 M
for FLC or voriconazole (VORI), 0.007 to 3.6 M for KTC, 0.004 to 8.32 M for
MCZ, 0.002 to 5.6 M for ITC, 0.200 to 103.5 M for R6G, 0.177 to 92.5 M for
ANISO, 0.066 to 35 M for CYH, 0.122 to 63 M for FK520, and 1.05 to 540 M
for CUR. Each checkerboard test generates many different combinations, and by
convention the FIC of the most effective combination is used in calculating the
FIC index.
Cytotoxicity assay. The cytotoxic effect of CUR was determined by an MTT
assay (3, 4). Yeast cells (104) were seeded into 96-well plates in the absence and
the presence of varying concentrations of CUR (25 to 500 M) and were grown
for 48 h at 30°C. One hundred microliters of an MTT solution was added to each
well and incubated for 3 to 4 h, and 200 l of isopropanol was added to stop the
reaction. Absorbance was measured using a microplate spectrophotometer at
570 nm with a reference wavelength of 650 nm. Cell survival (as a percentage of
the survival of control cells) was calculated as (mean absorbance in test wells)/
(mean absorbance in control wells)  100.
RESULTS
CUR inhibits R6G efflux. We used a commercial prepara-
tion of CUR in order to observe its effect on MDR efflux
proteins of the pathogenic yeast C. albicans. For this purpose,
we monitored the efflux of R6G in cells where GFP-tagged
CaCdr1p (Cdr1p-GFP) was stably overexpressed from a
genomic PDR5 locus in the S. cerevisiae mutant strain AD1-
8u (20). The host AD1-8u, constructed by Goffeau’s group
(7), was derived from a Pdr1-3 mutant strain with a gain-of-
function mutation in the transcription factor Pdr1p, resulting
in constitutive hyperinduction of the PDR5 promoter (20). As
shown in Fig. 1A, S. cerevisiae cells overexpressing CaCdr1p
showed energy-dependent efflux of R6G, which was inhibited
by CUR (100 M). However, the addition of CUR had no
effect on the leakage of preloaded R6G from de-energized S.
cerevisiae cells. We tested if CUR could also affect a multidrug
transporter belonging to the MFS, and we examined efflux
mediated by CaMdr1p expressed in a similar heterologous
background. As shown in Fig. 1B, the transport of [3H]MTX,
a well-known substrate of CaMdr1p, remained unaffected by a
fourfold excess of CUR. In the experiments for which results
are shown in Fig. 1A, strain AD-CaMDR1 was used as a
negative control for R6G transport, and in the experiments for
Fig. 1B, strain AD-CDR1 was used as a negative control for
MTX transport. The effect of CUR was also substrate specific,
as evidenced by the fact that efflux of the well-known substrate
FLC remained unimpeded in CaCdr1p-expressing S. cerevisiae
cells, even though CUR was supplied in a 1,000-fold excess
(Fig. 1C). Of note, CUR could also modulate R6G efflux in C.
albicans cells (Fig. 1D); however, for subsequent studies, we
used an S. cerevisiae strain overexpressing MDR transporters.
CUR selectively modulates ABC transporters. Before inves-
tigating whether CUR affects drug transporters, we examined
whether it affected the viability of cells. For this purpose,
control cells and transporter-overexpressing cells were exposed
to various concentrations of CUR for 48 h, and cytotoxicity was
determined by an MTT assay (3, 4). The percentage of viable
cells was calculated in order to determine the 50% inhibitory
concentrations (IC50s) (Fig. 2). As shown in Table 2, the IC50s
for control cells (AD1-8u) and those for cells expressing
various transporters (AD-CDR1, AD-CDR2, AD-PDR5, and
AD-CaMDR1) were not very different, ranging from 410.6 
9.4 M to 498  5.5 M. Further, our transport assays con-
firmed that CUR is not a substrate of ABC or MFS proteins,
since the extracellular concentration of CUR remained the
same even after the initiation of efflux (data not shown). Our
data suggest that CUR interacts with the yeast transporters,
but these multidrug transporters may not transport it, since the
IC50s and relative resistance factors were similar whether cells
were overexpressing a transporter or not. We investigated
whether the effect of CUR is specific to ABC transporters, and
we examined R6G efflux mediated by CaCdr1p homologues,
such as CaCdr2p and ScPdr5p, which were expressed in similar
backgrounds. It was observed that CUR could inhibit the efflux
of R6G mediated by both the proteins (Fig. 1E and F). Our
transport assays confirmed that CUR is not a substrate of ABC
or MFS proteins, since the extracellular concentration of CUR
remained the same even after the initiation of efflux (data not
shown). This was further confirmed by a cytotoxicity assay (3,
4), where the IC50s were similar for cells that did and did not
FIG. 2. Effect of CUR on the viability of S. cerevisiae cells as de-
termined by an MTT assay. Shown is the percentage of survival among
control cells (AD1-8u) (open circles) and among cells overexpressing
ABC or MFS transporters: AD-CDR1 (open inverted triangles), AD-
CDR2 (open triangles), AD-PDR5 (open diamonds), and AD-
CaMDR1 (open squares) cells. The experiments were conducted in
triplicate, and the values are means  standard deviations for three
independent experiments.
TABLE 2. IC50s and relative resistance factors for fungal strains in
the presence of CUR
Strain IC50 (M)
Relative
resistance
factor
AD1-8u 421.6  2.2 1
AD-CDR1 492.8  6.3 1.16
AD-CDR2 410.6  9.4 0.99
AD-PDR5 498  5.5 1.18
AD-CaMDR1 454.6  7.4 1.07
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overexpress transporters (Table 2). It should be mentioned
that the functionality of GFP-tagged versions of ABC and MFS
transporters was similar to that of untagged proteins (22, 27).
To further examine the effect of CUR, the ABC transporter
CaCdr1p was selected for detailed functional analyses.
CUR competitively inhibits R6G efflux. Commercially avail-
able CUR is a mixture of three major curcuminoids: curcumin,
or diferuloylmethane (curcumin I), demethoxycurcumin (cur-
cumin II), and bisdemethoxycurcumin (curcumin III). This
mixture contains predominantly curcumin I (77%), followed
by curcumin II (17%) and curcumin III (3%), which display a
wide range of biological and pharmacological properties (1,
16). We used purified curcuminoids (curcumins I, II, and III)
to see if these compounds showed any selectivity as modulators
of R6G efflux. The efflux of R6G mediated by CaCdr1p was
inhibited by all the pure forms of CUR in a concentration-
dependent manner, with IC50s ranging from 40  5 to 45  5
M (Fig. 3A). The Lineweaver-Burk plot revealed that CUR
competitively inhibits R6G efflux, with an increase in apparent
Km (5.87 to 11.83 M) but no effect on the Vmax (Fig. 4A).
CUR inhibits drug binding and has no effect on ATPase
activity or the expression of CaCdr1p. We had shown previ-
ously that IAAP (a photoaffinity analogue of the human P-
glycoprotein substrate prazosin) and azidopine (a dihydropyr-
idine photoaffinity analogue of its modulator, verapamil)
specifically bind to CaCdr1p (27). To monitor whether CUR
affects drug binding, we labeled CaCdr1p with [125I]IAAP as
described in Materials and Methods. Figure 4B demonstrates
that CUR effectively inhibited the photoaffinity labeling of
CaCdr1p with [125I]IAAP, with an IC50 of 14.2 M. We also
monitored [125I]IAAP labeling in the presence of R6G as de-
scribed in Materials and Methods. Interestingly, R6G could
not inhibit [125I]IAAP binding. In contrast to well-known in-
hibitors of CaCdr1p ATPase activity, such as vanadate, oligo-
mycin, sodium azide, and N-ethylmaleimide (15, 26, 27), CUR
at 100 M had no effect on ATPase activity in the presence of
varying concentrations of ATP (Fig. 4C). CUR also had no
effect on the expression of CaCdr1p (Fig. 4D). Taken together,
the data strongly indicate that although CUR is not trans-
ported, it acts as a competitive inhibitor at one of the transport
sites used to transport clinically significant antifungal agents.
CUR displays synergism with selected azoles. When the
control (AD1-8u) cells and the CaCdr1p-expressing cells
were grown either in the presence of drugs alone (FLC at 6.52
M, VORI at 5.72 M, MCZ at 0.167 M, KTC at 0.037 M,
ITC at 0.141 M, ANISO at 2.97 M, CYH at 0.28 M, FK520
at 12.6 M, R6G at 0.209 M) or in the presence of both CUR
(75.6 M) and the indicated drug, it was observed that
CaCdr1p-expressing cells displayed the expected drug resis-
tance and thus were able to grow in the presence of drug alone.
Similar results were obtained with CaCdr2p- and ScPdr5p-
expressing S. cerevisiae cells (data not shown). However, the
simultaneous presence of CUR with either R6G or azoles, viz.,
KTC, ITC, or MCZ, sensitized the cells, as evidenced by inhi-
bition of the growth of the cells (Fig. 5ii). Interestingly, the
presence of CUR along with noncompeting drugs, such as
ANISO, CYH, FLC, VORI, and FK520, did not affect the level
of resistance or the growth of cells expressing ABC proteins
(Fig. 5iii). The observed inhibition of growth by CUR in the
presence of drugs was not due to loss of viability, as deter-
mined by an MTT assay (Fig. 2). Notably, CUR (75.6 M)
alone did not inhibit the growth of control cells (AD1-8u) or
that of cells overexpressing CaCdr1p (Fig. 5i) or CaMdr1p
(Fig. 5iv). The growth of CaMdr1p-overexpressing cells in the
presence of MTX remained insensitive to CUR (Fig. 5iv). We
performed checkerboard assays in the presence of CUR and
various drugs. The FIC indices are below 0.5 for drugs such as
KTC, ITC, MCZ, and R6G in AD-CDR1 cells, suggesting
synergism with CUR (Table 3). Checkerboard analysis showed
no synergism with CUR for FLC, VORI, ANISO, CYH, or
FK520. Similar patterns of synergism between select drugs and
CUR were observed with AD-CDR2 and AD-PDR5 cells
(data not shown).
CUR acts at the R6G transport site. We had recently sub-
jected transmembrane segment 11 of CaCdr1p to alanine scan-
ning, replacing all 21 amino acid residues with alanine by
site-directed mutagenesis (24). Out of 21 residues of trans-
membrane segment 11, substitution of 5 residues, namely,
A1346G, A1347G, T1351A, F1360A, and G1362A, abrogated
the efflux of R6G, while the rest of the mutant variants of
CaCdr1p showed unaltered efflux (Fig. 6A). Since CUR selec-
tively modulates R6G efflux, we argued that if R6G and CUR
share binding sites, abrogation of R6G efflux should affect its
modulation by CUR. Interestingly, we observed that the ability
of CUR to modulate R6G efflux was indeed considerably re-
duced in those mutant variants that showed abrogated efflux of
R6G. Figure 6B shows that the percentage of inhibition of
R6G efflux by CUR was considerably lower in mutant variants
than in native CaCdr1p-expressing cells. In addition, CUR
inhibits R6G efflux even in those mutant variants that do not
show abrogated efflux of the dye. This would suggest that in
addition to common binding sites, CUR also has an indepen-
dent binding site(s) in CaCdr1p (Fig. 6C and D). However, to
resolve this issue, elaborate binding studies will be required.
DISCUSSION
Among the 28 putative ABC transporter genes and 95 pu-
tative MFS transporter genes identified in the C. albicans ge-
nome (9, 10), there is overwhelming clinical and experimental
evidence that only ABC transporters, such as CaCdr1p and
CaCdr2p, and the MFS transporter CaMdr1p are major deter-
minants of azole resistance (23, 25). The reversal of the func-
tionality of these multidrug efflux pump proteins represents an
FIG. 3. Effects of pure curcuminoids on R6G transport in S. cerevisiae cells overexpressing CaCdr1p. (A) Structures of curcumin I, curcumin
II, and curcumin III and competition assays with R6G. CaCdr1p-overexpressing S. cerevisiae cells were incubated either with 10 M R6G alone
or with 10 M R6G plus curcumin I, II, or III (10 to 100 M). R6G efflux was monitored 40 min after the addition of glucose (2%). Extracellular
R6G was quantified by measuring the absorbance at 527 nm. The data are plotted using GraphPad Prism. Values are means and standard
deviations (error bars) for three independent experiments. (B) Structures of the various substrates used.
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FIG. 4. Biochemical analysis of CaCdr1p in the presence of CUR. (A) Lineweaver-Burk plot of CaCdr1p-mediated R6G efflux in the presence of
CUR 5 min after the addition of 2% glucose. Filled diamonds, open squares, and filled triangles represent 0, 50, and 100 M CUR, respectively. The
rate of each reaction was calculated as nanomoles of R6G released per minute per 5 106 cells. (B) Effect of CUR or R6G on the photoaffinity labeling
of CaCdr1p with [125I]IAAP. The autoradiogram represents the amounts of [125I]IAAP incorporated into CaCdr1p in the presence of the indicated
concentrations of CUR or R6G. The graph represents the amounts of [125I]IAAP incorporated into CaCdr1p in the presence of the indicated
concentrations of CUR. (C) Effect of CUR on the ATPase activity of CaCdr1p. PMs from cells overexpressing CaCdr1p were incubated with or without
100 M CUR and varying concentrations of ATP (0.5 mM to 7 mM) in the ATPase buffer. The assay was performed essentially as described in Materials
and Methods. The data are plotted using GraphPad Prism. (D) Effect of CUR (100 M) on the expression of CaCdr1p. Western blot analyses were
performed with an anti-GFP monoclonal antibody. Equal loading of protein was assessed by using a Coomassie-stained gel.
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attractive strategy for combating azole resistance. In this study,
we explored whether CUR, which inhibits the activities of the
mammalian ABC multidrug transporter genes ABCB1,
ABCG2, and ABCC1 (3, 4, 5), could be exploited as a modu-
lating agent for multidrug transporters of C. albicans. Our
study reveals that CUR inhibited R6G transport exclusively in
S. cerevisiae cells overexpressing the ABC drug transporters
CaCdr1p, CaCdr2p, and ScPdr5p and had no effect on efflux
mediated by the MFS transporter CaMdr1p. All three pure
forms of CUR—curcumins I, II, and III—showed similar levels
of modulation of R6G efflux in S. cerevisiae cells expressing
ABC transporters (Fig. 3A). The modulatory effect of CUR
was restricted to R6G; it had no effect on the efflux of another
substrate, FLC. We could observe a direct correlation between
the modulatory effect of CUR and the status of R6G efflux. For
instance, those mutant variants of CaCdr1p that show abro-
gated efflux of R6G also display decreased modulation by
CUR.
Notably, R6G and FLC are both substrates of CaCdr1p, but
only the former is competed with CUR (Fig. 1A and C). If the
structure of CUR is compared with the structures of R6G and
FLC, it is apparent that electronic factors, such as the number
of 	 rings and an extended 	 surface, could be important for
CUR and other substrates, such as ITC, KTC, and MCZ,
which compete with R6G efflux (Fig. 3B). In this context, it is
noteworthy that noncovalent 	-	 interactions have tremen-
dous biological implications (13, 14). On the other hand, if one
considers the structures of FLC, VORI, ANISO, and CYH,
which do not compete with R6G, there are no such electronic
factors but a good number of tetrahedral sites. Therefore,
these subtle differences in properties between the structures of
competing and noncompeting substrates could explain why
CUR is a selective modulator.
The probability that the modulation of ABC transporter
function would result in an increase in the intracellular con-
centrations of the drugs to toxic levels became apparent from
the growth studies. When CUR was used in combination, it
was synergistic with drugs in cells overexpressing ABC trans-
porters. This synergism was restricted to those drugs whose
efflux was modulated by R6G (24). Thus, the chemosensitiza-
tion of cells by CUR was specific to competing drugs, such as
KTC, ITC, and MCZ, and was not observed with noncompet-
itive drugs, such as FLC, VORI, ANISO, CYH, and FK520.
The fact that the presence of CUR along with some drugs did
not inhibit the growth of cells not only points to the selectivity
of CUR for certain compounds but also suggests that R6G,
KTC, ITC, MCZ, and CUR may share overlapping binding
sites of ABC multidrug transporter proteins. The modulatory
and synergistic effects of CUR confirm our previous observa-
tion that KTC, MCZ, and ITC share CaCdr1p binding sites
with R6G (24).
A natural CUR mixture contains three major curcumi-
noids: curcumin I, curcumin II, and curcumin III. We tested
these individual curcuminoids in our earlier studies with the
mammalian ABC drug transporters P-glycoprotein, MRP1,
FIG. 5. Synergistic effects of CUR on drug resistance. Control
(AD1-8u) and CaCdr1p-expressing (AD-CDR1) S. cerevisiae cells
were grown overnight on YEPD plates and then resuspended in nor-
mal saline to an optical density at 600 nm of 0.1. The following stock
solutions of drugs were used: R6G at 1 mg/ml in dimethyl sulfoxide,
FLC at 1 mg/ml in water, VORI at 5 mg/ml in water, CYH at 0.1 mg/ml
in water, MCZ at 1 mg/ml in methanol, KTC at 1 mg/ml in methanol,
ANISO at 1 mg/ml in dimethyl sulfoxide, FK520 at 1 mg/ml in ethanol,
MTX at 1 mg/ml in 10 mM Tris-Cl, and CUR at 11 mg/ml in dimethyl
sulfoxide. Five microliters of a fivefold serial dilution of each strain was
spotted onto YEPD plates as described previously (27) either in the
absence (control) (i) or in the presence of antifungals, alone or in
combination with CUR (ii through iv). (ii) R6G (0.209 M), ITC
(0.141 M), KTC (0.037 M), or MCZ (0.167 M), alone or in com-
bination with CUR (75.6 M). (iii) FLC (6.52 M), ANISO (2.97
M), CYH (0.28 M), FK520 (12.6 M), or VORI (5.72 M), alone
or in combination with CUR (75.6 M). (iv) MTX (11 M) or CUR
(75.6 M), alone or in combination. TABLE 3. Interaction of CUR with KTC, MCZ, ITC, or R6G
against AD-CDR1 cellsa
Antifungal
or dye
FIC of the
antifungal or dye FIC of CUR FICI
KTC 0.25 0.0054 0.255
MCZ 0.125 0.005 0.130
ITC 0.250 0.005 0.255
R6G 0.0026 0.0013 0.0039
a Evaluated by the checkerboard method recommended by the CLSI and
expressed as the FIC index (FICI). A FICI of 0.5 indicates synergistic inter-
action. FICI is calculated as the sum of the FICs of each agent. The FIC of each
agent is calculated as the MIC of the agent in combination divided by the MIC
of the agent alone (21).
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and ABCG2 (3, 4, 5). We reported that these individual
curcuminoids inhibited the function of these drug transport-
ers with different efficiencies and that curcumin I was the
most potent among them (3, 4, 5). In addition, we have also
reported that tetrahydrocurcumin, a major metabolite of
CUR, also inhibits these three mammalian ABC drug trans-
porters (18). In this study, based on the initial data discussed
above for the natural CUR mixture and its purified individ-
ual components with mammalian transporters, we evaluated
the CUR mixture alone for its activity to synergize the
activities of antifungal agents. There are several CUR de-
rivatives that are synthetic analogues, and some of them may
have better activity than the CUR mixture. Thus, these
analogues merit further study.
There are reports to suggest that CUR can downregulate
the expression of an MDR-linked transporter (ABCB1) and
can even affect the function of several transcription factors
(2, 6). For this reason, we tested the effect of CUR on the
expression of an ABC transporter and observed that CUR
did not affect the expression levels of CaCdr1p (Fig. 4D),
implying that the modulation of R6G efflux by CUR is
restricted to its direct effect on the functionality of ABC
transporter proteins. The direct effect of CUR on CaCdr1p
was confirmed by its ability to compete the photoaffinity
labeling of CaCdr1p with [125I]IAAP (Fig. 4B) and by its
competitive inhibition of R6G efflux (Fig. 4A). We excluded
the possibility that CUR could be a preferred substrate of
the ABC transporters studied (Fig. 2).
Our study shows that CUR, which is not a transport sub-
strate of CaCdr1p, specifically modulates the efflux of R6G
mediated by the transporter. This is not surprising, since it
has been observed previously that curcuminoids can modu-
late drug transport without being a substrate of mammalian
ABCG2 (4). Our cytotoxicity data (Fig. 2; Table 2) suggest that
the presence or absence of efflux pump proteins did not affect
the growth and viability of yeast cells, again pointing to the fact
that CUR is not a substrate of these pumps. It is not clear,
however, whether CUR modulates R6G efflux by binding to
the substrate or to an allosteric site(s) of CaCdr1p. Consider-
ing the fact that the structures and substrate specificities of
fungal ABC transporters such as CaCdr1p, CaCdr2p, and
ScPdr5p are very different, our finding from this study that
yeast transporters can be modulated by CUR is very signifi-
cant.
It is reported that the poor bioavailability of CUR and its
low concentrations in plasma decrease its effectiveness in
modulating the function of ABC drug transporters in ro-
dents and humans. However, recent studies indicate that the
use of piperine to prevent the glucuronidation of curcumin,
as well as the encapsulation of CUR in liposomes, can in-
crease the absorption of CUR and its levels in plasma (28).
It is, however, not known whether CUR is metabolized via
glucuronidation in yeast cells or whether the intracellular
FIG. 6. R6G transport in S. cerevisiae cells overexpressing
CaCdr1p or its mutant variants. (A and C) Extracellular R6G con-
centrations (expressed as percentages of those with wild-type
CaCdr1p [AD-CDR1 cells]) in S. cerevisiae cells overexpressing
CaCdr1p or mutant variants of CaCdr1p, incubated with 10 M
R6G alone. Energy-dependent R6G efflux was initiated by adding
2% glucose and was quantified by measuring the absorbance of the
supernatant at 527 nm. (B and D) Percentages of inhibition of R6G
efflux by CUR (100 M), calculated by taking the level of R6G
efflux with each mutant CaCdr1p variant in the absence of CUR as
100%. Values are means  standard deviations (error bars) for
three independent experiments.
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level of CUR is lower than that in medium or plasma. These
issues need to be resolved before CUR can be used as an
effective in vivo or in vitro antifungal. In summary, the
modulation of antifungal efflux by CUR is substrate and
transporter specific. Nevertheless, curcuminoids are not
toxic to the cell, nor are they transported by their target
efflux pumps. Thus, their ability to sensitize cells to azoles
opens up the possibility that they could be exploited in
combination with conventional chemotherapy.
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